Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Tina Tan
Underlining its focus on 3D-printing and the potential this technology can bring, DePuy Synthes has acquired the 3D-printed scaffold platform of Tissue Regeneration Systems, enabling the orthopedics leader to develop patient-specific trauma products in-house.
Medtronic is selling certain lower-margin, lower growth assets within its Patient Monitoring and Recovery division to Cardinal Health in a $6.1bn deal. While the deal may benefit Medtronic's debt situation, the same cannot be said for the buyer.
With another fresh injection of funds from the UK Medical Research Council, imaging services provider Imanova is advancing to the next stage of its MIND-MAPS program that aims to identify novel early markers of progression of neurodegenerative diseases, including Alzheimer's and Parkinson's. The data generated from the program could be used to help Imanova's pharma partners develop new therapies to tackle these diseases.
From crowdfunding to taking on its distributor partner as investor, the varied fundraising routes that HiberGene traveled down for its series B round has enabled the Irish rapid molecular diagnostic test developer to raise €6.7m.
While the in vitro diagnostics landscape has seen players come and go, Roche Diagnostics has remained at the top. But the Swiss giant, like all its other smaller rivals, is facing a new reality, with increasing pressures to prove medical value, and a more stringent regulatory environment. Medtech Insight spoke to Roche Diagnostics' Jean-Claude Gottraux, head of centralized and point of care solutions, and Jean-Jacques Palombo, lifecycle leader for the company's cardiac, women's health and personalized health care solutions immunoassay portfolio, to gain their perspectives on how the sector has evolved and will continue to evolve. They also spoke about the company's strategy to address these changes and challenges.
It had been a slow start to the year but one unusually large financing round from cancer diagnostics company Grail means the first quarter of 2017 has now outpaced the performance from any in the previous four years.